Alembic Pharmaceuticals Limited
Valuation (93/100) does the heavy lifting; quality (55/100) is the drag.
Buy zoneAlembic Pharmaceuticals Limited earns a Buy from StocksWizard, with a blended score of 71/100. At ₹797.05 it trades below our blended DCF and relative-multiples fair value of ₹1,350.75, about 69% upside to that estimate — we read it as undervalued by 69%. On 22.7x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 19% below its 52-week high of ₹978.4 and 25% above the low of ₹637.08. Financial health scores 95/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹907.2 implies about 14% upside across 10 analysts. It clears 9 of 13 investability checks, with durability 55, valuation 86 and momentum 68 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,080.6.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-18.54% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy71Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 12.4%
- Pass: Low debt (D/E < 0.5): 0.25x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 4%
- Pass: Earnings growing: 29%
- Fail: Net margin ≥ 10%: 9.2%
- Pass: Current ratio > 1.5: 1.76
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.79
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter70.7%
- Institutions17.2%
- Public & other12.1%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 4.79.
Opportunities
- Earnings growing (29% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~70% below our estimated fair value.
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is an integrated pharmaceutical company that develops, manufactures, and markets pharmaceutical products across India and international markets. It offers formulations spanning therapeutic areas including cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough treatments, and animal health, along with generic oral solids, oncology oral solids, and injectables.
Alembic Pharmaceuticals Limited — frequently asked questions
Is Alembic Pharmaceuticals Limited a buy, hold or sell?
StocksWizard currently rates Alembic Pharmaceuticals Limited (APLLTD) a Buy, based on a blended score of 71/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Alembic Pharmaceuticals Limited's fair value?
Our blended DCF and relative-valuation model estimates Alembic Pharmaceuticals Limited's fair value at about ₹1,350.75, versus a current price of ₹797.05 — roughly 69% upside. On that basis the stock looks undervalued by 69%.
Is Alembic Pharmaceuticals Limited financially healthy?
Alembic Pharmaceuticals Limited scores 95/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Alembic Pharmaceuticals Limited's share price performed?
Alembic Pharmaceuticals Limited is up 5% over three months, and last traded at ₹797.05. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.